XOMA Corporation (XOMA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Mar, 2026Executive summary
Annual meeting scheduled for May 21, 2026, to be held virtually, with voting on key proposals including director elections, auditor ratification, equity plan amendments, and executive compensation.
Proxy materials and annual report are available online, with a focus on reducing paper and mailing costs.
Shareholders of record as of March 25, 2026, are eligible to vote; quorum requires a majority of voting power.
Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Election of seven directors to serve until the 2027 annual meeting.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026.
Approval of amendment and restatement of the 2010 Long Term Incentive and Stock Award Plan, increasing share pool by 425,000 shares and extending plan term to 2036.
Approval of the 2026 Employee Stock Purchase Plan, authorizing 500,000 shares for issuance.
Advisory vote on executive compensation (say-on-pay).
Shareholder proposals for the 2027 meeting must be submitted by November 30, 2026.
Board of directors and corporate governance
Board consists of seven members with diverse backgrounds; 42% female, 14% racially/ethnically diverse, 14% LGBTQ+.
Chairman is independent; CEO and Chairman roles are separated.
All directors attended at least 75% of meetings in 2025.
Four standing committees: Audit, Compensation, Nominating & Governance, and Transaction.
Insider trading policy prohibits hedging, short sales, and pledging of company stock.
Latest events from XOMA Corporation
- Virtual annual meeting to vote on directors, auditor, incentive plans, and executive pay.XOMA
Proxy filing30 Mar 2026 - Royalty receipts rose 68% and the portfolio doubled, fueling strong cash flow and profitability.XOMA
Q4 202518 Mar 2026 - Diversified royalty portfolio, strong cash flow, and major pipeline catalysts ahead.XOMA
Leerink Global Healthcare Conference 202611 Mar 2026 - Diversified royalty portfolio, multiple phase III catalysts, and profitability targeted by 2027.XOMA
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Biotech royalty aggregator grew to 100+ assets, with strong cash flow and key 2026 milestones ahead.XOMA
Corporate presentation2 Mar 2026 - Scalable royalty aggregation model targets early-stage biotech assets for sustained growth.XOMA
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Targets early-stage biotech royalties for high-margin, long-term cash flow and disciplined growth.XOMA
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Early-stage asset focus and scalable model set to drive royalty growth and cash flow ramp.XOMA
Leerink Global Healthcare Conference 202526 Dec 2025 - Scalable royalty aggregation and disciplined capital deployment drive growth from 130+ biotech assets.XOMA
Jones Healthcare and Technology Innovation Conference 202523 Dec 2025